Clinical Trial: UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07001254) titled 'UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia' on May 23.

Brief Summary: This Phase II open-label interventional clinical trial aims to evaluate the efficacy of romiplostim, in patients with severe aplastic anemia (SAA), both treatment naive and relapsed/refractory, in inducing trilineage hematopoiesis in children and young adults.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Aplastic Anemia

Intervention: DRUG: Romiplostim

The investigational drug, Romiplostim, is a thrombopoietin receptor agonist (TPO-RA) that has been granted orphan ...